Patents by Inventor Markus Kalesse

Markus Kalesse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biphenyl compounds for use in treating malaria and other parasitic disorders
    Patent number: 9499471
    Abstract: The present invention relates to a compound of formula (I) as defined herein.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: November 22, 2016
    Assignee: Medizinische Hochschule Hannover
    Inventors: Dietmar Manstein, Matthias Preller, Marcus Furch, Markus Kalesse, Nina Diaz-Gomez
  • Method for producing intermediates for the production of novel macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof, and uses of said macrocycles
    Patent number: 9458200
    Abstract: The present invention relates to the use of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular argyrin and derivatives thereof, for a treatment in a variety of conditions, such as the induction of immunotolerance, autoimmune diseases, bacterial infections, and proliferative diseases, such as cancers.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: October 4, 2016
    Assignees: Gottfried Wilhelm Leibniz Universität Hannover, Medizinische Hochschule Hannover, Helmholtz-Zentrum für Infektionsforschung GmbH
    Inventors: Markus Kalesse, Nisar Malek, Ronald Frank, Tobias Brodmann, Leila Bülow, Andreas Rentsch, Anna-Katharina Girbig, Ulrike Eggert
  • BIPHENYL COMPOUNDS FOR USE IN TREATING MALARIA AND OTHER PARASITIC DISORDERS
    Publication number: 20150274637
    Abstract: The present invention relates to a compound of formula (I) as defined herein.
    Type: Application
    Filed: September 10, 2012
    Publication date: October 1, 2015
    Applicants: Gottfried Wilhelm Leibniz Universitaet Hannover, Mediziniche Hochschule Hannover
    Inventors: Dietmar Manstein, Matthias Preller, Marcus Furch, Markus Kalesse, Nina Diaz-Gomez
  • Method for producing intermediates for the production of macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof
    Patent number: 8853249
    Abstract: The present invention relates to an improved method for the synthesis of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular argyrin and derivatives thereof.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: October 7, 2014
    Assignees: Helmholtz-Zentrum für Infektionsforschungs GmbH, Medizinische Hochschule Hannover, Gottfried Wilhelm Leibniz Universität
    Inventors: Markus Kalesse, Ulrike Eggert
  • Method For Producing Intermediates For The Production Of Macrocycles That Are Inhibitors Of The Proteasomic Degradation of P27, Such As Argyrin And Derivatives Thereof
    Publication number: 20120295941
    Abstract: The present invention relates to an improved method for the synthesis of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular argyrin and derivatives thereof.
    Type: Application
    Filed: December 14, 2010
    Publication date: November 22, 2012
    Inventors: Markus Kalesse, Ulrike Eggert
  • Method for Producing Intermediates for the Production of Novel Macrocycles that are Inhibitors of the Proteasomic Degradation of p27, such as Argyrin and Derivatives Thereof, and Uses of Said Macrocycles
    Publication number: 20110311564
    Abstract: The present invention relates to the use of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular argyrin and derivatives thereof, for a treatment in a variety of conditions, such as the induction of immunotolerance, autoimmune diseases, bacterial infections, and proliferative diseases, such as cancers.
    Type: Application
    Filed: June 23, 2009
    Publication date: December 22, 2011
    Inventors: Markus Kalesse, Leíla Bülow, Andreas Rentsch, Anna-Katharina Girbig, Ulrike Eggert, Nisar Malek, Ronald Frank, Tobias Brodmann
  • Ratjadone derivatives for inhibiting cell growth
    Publication number: 20040092581
    Abstract: The invention relates to ratjadone derivatives which can stop the cell cycle of tumour cells in the G1 phase and/or exhibit a reduced cytotoxicity as ratjadone. According to the invention, the ratjadone derivatives correspond to formula (II) wherein R1, R2 and R3 are selected independently from each other from the group which is made of H, CH3 and C2H5, R4 is CH3 or C2H5, R5 is H or OH and R6 and R7 are selected independently from each other from the group which is made of H, CH3, C2H5, n-C3H7, and iso C3H7, and wherein C10 is R-configured and C17 is R-configured if (a) C16 is R-configured and simultaneously (b) neither R5, nor R6, nor R7 are H. The invention also relates to a method for synthesizing ratjadone derivatives.
    Type: Application
    Filed: August 12, 2003
    Publication date: May 13, 2004
    Inventors: Arne Burzlaff, Cornelia Kasper, Thomas Scheper, Markus Kalesse, Ulhas Bhatt, Khandavalli Chary, Eckhard Claus, Mathias Christmann, Monika Quitschalle, Winfried Beil